Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05047133 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Early Administration of TXA in Adult Hip Fractures

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 16, 2021 (before its estimated July 1, 2022 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.
Trial Details
NCT Number NCT05047133
Lead Sponsor Ascension Health
Conditions
(from sponsor)		 Postoperative Blood Loss
Related terms Postoperative Hemorrhage
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov